A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy and Safety of CAM-3001 in Subjects With Rheumatoid Arthritis.

Trial Profile

A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy and Safety of CAM-3001 in Subjects With Rheumatoid Arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Mavrilimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms EARTH
  • Sponsors MedImmune
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jun 2015 Results (pooled analysis of EARTH and EARTH EXPLORER-1 trials) presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 29 Oct 2013 Results of a biomarker analysis presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top